Netarsudil Mesylate

Reduces elevated intraocular pressure (IOP). Sold as Rhopressa. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Netarsudil Mesylate (sold as Rhopressa), first approved Dec 18, 2017, with 0 new uses approved and 0 published complete response letters.

First approved: Dec 18, 2017
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $172M
First approved in the EU: Nov 19, 2019

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Rhopressa	Part D	$172M	+3%	87,405

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

RHOPRESSA 0.02% OPHTH SOLUTION: $131.68 per MLBrand · +3% in a year

Approvals in the EU (EMA)

First approved in the EU 23 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals

Rhokiinsa, new substanceSanten Oy · Nov 19, 2019

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 18, 2017	RhopressaNDA 208254 · New molecular entity	Alcon Labs Inc	2	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA